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Abstract
Background: Multiple sclerosis (MS) is an incurable, unpredictable but typically progressive neurological condition.
It is the most common cause of neurological disability in young adults. Within 15 years of diagnosis, approximately
50 % of affected people are unable to walk unaided, and over time an estimated 25 % depend on a wheelchair.
Typically, people with such limited mobility are excluded from clinical trials. Severely impaired people with MS
spend much of their day sitting, often with limited ability to change position. In response, secondary complications
can occur including: muscle wasting, pain, reduced skin integrity, spasms, limb stiffness, constipation, and
associated psychosocial problems such as depression and lowered self-esteem. Effective self-management
strategies, which can be implemented relatively easily and cheaply within people’s homes, are needed to improve
or maintain mobility and reduce sedentary behaviour. However this is challenging, particularly in the latter stages of
disease. Regular supported standing using standing frames is one potential option.
Methods/Design: SUMS is a pragmatic multi-centre randomised controlled trial evaluating use of Oswestry
standing frames with blinded outcome assessment and full economic evaluation. Participants will be randomly
allocated (1:1) to either a home-based, self-management standing programme (with advice and support) along
with their usual care or to usual care alone. Those in the intervention group will be asked to stand for a minimum
of 30 min three times weekly over 20 weeks. Each participant will be followed-up at 20 and 36 weeks post baseline.
The primary clinical outcome is motor function, assessed using the Amended Motor Club Assessment. The primary
economic endpoint is quality-adjusted life years. The secondary outcomes include measures of explanatory physical
impairments, key clinical outcomes, and health–related quality of life. An embedded qualitative component will
explore participant’s and carer’s experiences of the standing programme.
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Discussion: This is the first large scale multi-centre trial to assess the clinical and cost effectiveness of a home
based standing frame programme for people who are severely impaired by MS. If demonstrated to be effective and
cost-effective, we will use this evidence to develop recommendations for a health service delivery model which
could be implemented across the United Kingdom.
Trial registration: ISRCTN69614598
Date of registration: 3.2.16 (retrospectively registered)
Keywords: Progressive Multiple Sclerosis, Standing, Standing frame, Physiotherapy, Self-management, Cost
effectiveness, Mobility
Background
Multiple sclerosis (MS) is an incurable, unpredictable
but typically progressive, life-long, neurological condi-
tion, affecting approximately 100,000 people in the
United Kingdom (UK) [1]. It is the most common cause
of neurological disability in young adults, with an esti-
mated cost of £1.4 billion/annum to the National Health
Service (NHS) and society [2]. Although most people
start with a relapsing-remitting disease course, approxi-
mately two-thirds move to a progressive phase within
eight years, at which point medical interventions are
limited. Within 15 years of diagnosis, an estimated 50 %
of affected people are unable to walk unaided, and over
time 25 % become dependent on a wheelchair [3]. It is,
therefore, unsurprising that mobility is a major concern
for people with MS and health professionals. Surveys of
people with MS consistently rank mobility as their high-
est priority [4, 5] and most important yet most challen-
ging daily function [6]. Mobility has been correlated
negatively with employment status and quality of life [2].
Evidence shows that enhancing physical activity and re-
ducing sedentary behaviour can improve mobility and
directly associated complications [7], providing a persua-
sive argument for ensuring that optimal physical man-
agement is a clinical priority.
NICE Guidelines emphasise that mobility spans much
more than simply walking [7], including activities neces-
sary for daily functioning: the ability to stand, safely
transfer from wheelchair to toilet or to bed, and to move
in bed. People with MS who are severely impaired spend
much of their day sitting, often with limited ability to
change position. In response, secondary complications
can occur rapidly, including muscle wasting, pain, re-
duced skin integrity, spasms, limb stiffness, constipation,
and associated psychosocial problems such as depression
and lowered self-esteem [8]. These secondary problems
can accelerate the loss of independence in daily function,
and can impact negatively upon quality of life [4, 9] and
self-identity. The clinical significance of these issues is
underlined by their consistent prominence in policy doc-
uments for long-term neurological conditions [7, 10].
There are also significant economic costs related to in-
creasing immobility and secondary complications since
they increase the burden of care, delay rehabilitation and
increase healthcare costs. It is estimated that approxi-
mately 15 % of people with MS will, at some point in
time, develop a pressure sore [11], with treatment costs
of a single pressure sore ranging from £1,064 to £24,214
[6]. The mean cost per wheelchair dependent patient is
4–5 times higher than an ambulatory patient [12]. This
clearly has significant implications to the health services.
Evidence from studies of a range of neurological con-
ditions, including MS, shows that increasing physical ac-
tivity by interventions such as physiotherapy, can
improve balance and mobility and reduce associated sec-
ondary health problems which arise from immobility [7].
However, increasing physical activity is difficult when
disability is severe. Physiotherapy typically comprises
short intermittent episodes of face-to-face sessions. On-
going physiotherapy is rarely possible due to resource re-
strictions [13, 14]. While group-based exercise programmes
are becoming more common, they can be inaccessible,
and may have inappropriate content, for people with se-
vere impairments [15]. Effective self-management strat-
egies, which can be implemented relatively easily and
cheaply within people’s homes, are needed for severely im-
paired individuals to improve or maintain their ability to
move and reduce their sedentary behaviour. However this
is challenging, particularly in the latter stages of disease.
Regular supported standing using standing frames is one
potential self-management option.
A systematic review investigating effectiveness of sup-
ported standing in neurological conditions [8], provided
some data to support its acceptability, feasibility and effi-
cacy but highlighted that more robust evidence is re-
quired. Of 17 randomised controlled trials (RCTs), only
two were of high quality, and only one trial involved
people with MS [16], which was a short-term, hospital
based programme. Our updated literature search add-
itionally identified one mixed-methods study [17] and a
qualitative study [18], but no further RCT’s investigating
this aspect of MS rehabilitation management.
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Among the work of this research team, a study be
Hendrie et al., has provided compelling evidence of the
need for a trial of a managed standing frame programme.
This study used a mixed-methods approach involving nine
in-depth single case studies [17] to provide an in-depth
understanding of the experiences of people with MS who
participated in the standing programme. Over the course
of a year, in addition to a range of objective measures,
Hendrie undertook 27 in-depth interviews. Respondents’
stories reveal how the programme enabled them to
“reconnect with their body”, “regain lost skills”, and
gain a sense of “being in control”. In line with other
related research [18] these interviews provided con-
vincing qualitative evidence that this self-management
standing programme reinstated a sense of belonging
and optimism about the future by restoring important
life roles and feelings of normality. A particularly de-
bilitating secondary complication of immobility is
stiff/hypertonic muscles. Our laboratory-based studies
[19] determined that the duration and magnitude of
force required to ease the stiffness in hypertonic lower
limb muscles could only be achieved in a supported
standing position for more severely impaired people
with MS.
The proposed study builds on these existing research
strands, asking the question “What is the clinical and
cost effectiveness of a home-based self-management stand-
ing frame programme in people who are severely impaired
with progressive MS?” The aim of this definitive multi-
centre randomised controlled study is to investigate the
clinical and cost effectiveness of a home-based supported
standing programme for people severely impaired with
progressive MS.
More specifically, the objectives are to:
1. Assess the clinical effectiveness of the standing
frame programme in improving motor function
(primary outcome).
2. Assess the clinical effectiveness of the standing
frame programme in improving balance, muscle
strength, joint and muscle range, painful spasms,
respiratory, bladder and bowel function, number of
falls and quality of life (secondary outcomes).
3. Establish the cost-effectiveness of the standing frame
programme versus usual care.
4. Explore the subjective experience of using a standing
frame within the home, from the perspective of both
the person with MS and their carer.
Methods
Trial design
This is a pragmatic multi-centre randomised controlled
trial with blinded outcome assessment and full economic
evaluation. Figure 1 shows the participant pathway.
Study Setting
Eight healthcare sites will be involved in this multi-
centred RCT which is based in two geographical regions
of England: Devon/Cornwall and East Anglia. Each site




Our primary outcome is the Amended Motor Club As-
sessment (AMCA) at 16 weeks follow-up. Our primary
analysis will utilise analysis of covariance (ANCOVA),
comparing AMCA scores at week 36 between allocated
groups, adjusting for baseline AMCA score. The trial is
powered to detect a between-group difference of nine
points which is both plausible and considered clinically
relevant [17, 20]. In people with severe MS a score
change of 9 points is considered clinically significant,
reflecting changes such as allowing a person to balance
and lean forwards in sitting to dress themselves or to
stand in the shower and wash their hair with two hands.
Estimates of final SD and baseline/follow-up correl-
ation for AMCA are subject to uncertainty and thus we
have used conservative 80 % upper confidence limits for
both parameters in our calculations. To detect a between-
group difference of nine points, with 80 % power and at
the 5 % significance level, requires data from 55 partici-
pants per group [21].
Allowance is required for people not completing the
programme, and for participants not attending the final
follow-up assessment. Based on our previous experi-
ences, we have allowed for 20 % loss to follow-up.
Therefore the sample size required is 69 participants per
group, rounded to a total of 140. An estimated 380
people will need to be screened to achieve the required
sample size.
Inclusion criteria
The study population will comprise individuals diagnosed
with primary or secondary progressive MS according to
McDonald’s criteria [22].
These participants will:
 be aged >18 years
 be willing and able to consent to participate
 score 6.5–8.0 on the Expanded Disability Status
Scale (EDSS), i.e. people who “require bilateral
assistance to walk 20 metres or less” to those
“restricted to bed or wheelchair”
 be able to get into a standing frame independently
or with assistance from one person
 have the agreement of another person (e.g. carer)
should assistance be necessary for the standing
programme
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Fig. 1 Trial flow chart of participant pathway
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 be able and willing to accommodate the standing
frame in their home
 be willing and able to travel to local assessment
centres for blinded outcomes assessment
Exclusion criteria
Participants will be excluded if they:
 have had any recent changes in disease modifying
therapies. More specifically they will be excluded if:
they have ever had Alemtuzumab, are within past
six months of ceasing Nataluzimab, or are within
three months of ceasing any other MS disease
modifying drug
 have relapsed/received steroid treatment within the
last month
 are currently undertaking a regular standing frame
programme (>x1/week), or have done so during the
past six months
 have a history of osteoporotic-related fractures
 have co-morbidities which contraindicate standing
in the frame (e.g. foot ulceration, uncontrolled
epilepsy) or likely to impact on the trial (e.g. chronic
jaundice, heart disease, age related multiple
co-morbidities)
 currently participating in another clinical trial
(rehabilitation or pharmacological)
Identification and recruitment of participants will be
via a number of routes which include screening MS
databases, identification by healthcare professionals, and
advertising via MS support groups and newsletters.
Randomisation
Participants will be randomised immediately after the
baseline assessment. Randomisation, using random sized
permuted blocks, will be on a 1:1 basis to receive the
intervention plus usual care or usual care only. It will be
stratified by region and baseline EDSS (≤7.0 or ≥7.5).
The allocation sequence is computer-generated by the
local United Kingdom Clinical Research Collaboration
Registered Peninsula Clinical Trials Unit (UKCRC
PenCTU) (Registration Number 31) in conjunction with
an independent statistician who will have no involve-
ment with the final analysis. Following assessment, the
blinded assessor will input the details of the participants
directly into the randomisation web-site. This will gener-
ate an e-mail stating the participant’s allocated treatment
group to the regional study co-ordinators and study ad-
ministrator to notify them of the treatment allocation.
Blinding
The trial participants and carers are unable to be blinded
in this trial due to the nature of the intervention.
Similarly, the treating physiotherapists and health care
providers are unable to be blinded. However, the out-
come assessors will be blinded to participants’ allocated
group. All assessments will be undertaken in separate
visits independently of delivery of treatment/usual care
and away from the participant’s home. Every effort will
be made throughout the trial to ensure these assess-
ments are blinded. Upon any interaction with the par-
ticipant, the blinded assessors will remind participants
not to discuss their allocated group, and this will be re-
iterated within any written and telephone
correspondence.
At each assessment time point, the blinded assessor
will be asked to record on a standardised form whether
or not they were un-blinded to the group allocation, and
if so the reasons for this.
Interventions
Participants in the intervention group will be asked to
stand in an Oswestry standing frame [17] for 30 min
three times per week for a total of 16 weeks during a
20 week period. The Oswestry standing frame is a
wooden frame, used in clinical practice, which provides
support in standing whilst allowing for exercise and con-
trolled movement.
The treating physiotherapist will teach the participant
and carer safe and effective use of the standing frame
over two face-to-face sessions in the participant’s home
(~60 min/session). Participants will also be taught exer-
cises and stretches to undertake in the frame. A detailed
user-friendly information leaflet and digital versatile disc
(DVD) will be provided to support these sessions. Fur-
ther support will be provided by weekly telephone con-
tact for four weeks, and then monthly for two months.
Telephone calls will focus on facilitating individuals to
set and achieve personal targets.
Standardisation and fidelity of the intervention
Treating physiotherapists from each of the eight health-
care sites will perform the interventions as part of their
NHS role; all physiotherapists will implement the inter-
vention in a similar manner.
Use of standing frames is incorporated within under-
graduate physiotherapy training and is a recognised core
skill for neurological physiotherapists. To standardise
and optimise implementation of the intervention, treat-
ing therapists, participants and carers will be provided
with an information pack. This includes a written tem-
plate of what is required to be undertaken within each
session and a link to the study web-site, which houses a
range of resources including a detailed booklet, instruc-
tional video with suggested exercise/stretches/balance
activities, and evidence based articles on this topic.
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All treating therapists will be required to complete a
pre-formatted checklist to self-assess their fidelity with
the content of the sessions. They will be asked to record
any deviations from the protocol on a Protocol Devia-
tions form. In addition, 10 % of the intervention sessions
will be assessed in each region by the unblinded regional
Principal Investigator who will observe the home-based
treatment sessions and independently complete the same
fidelity checklist.
Usual care
This trial will use a usual clinical care control group. A
recent MS Society national survey demonstrated that ac-
cess to physiotherapy services varies throughout the UK/
England [14]. Although usual care varies between indi-
viduals [1], it rarely involves regular physiotherapy inter-
vention either within the community or hospital [13].
Any intervention is generally limited to a few visits, typ-
ically reacting to presenting problems (e.g. practising
transfer skills, providing mobility aids) rather than pro-
moting long-term preventative self-management [13].
This national picture reflects the care provided in our
study regions. The usual care received (including fre-
quency of physiotherapy intervention as well as any
other health/social service interventions and medica-
tions) will be recorded within the economic cost effect-
iveness assessments.
Data collection and outcome measurements
Standardised, validated clinician-rated and patient self-
reported clinical outcomes will be measured at baseline,
immediately post intervention (20 weeks) and follow-up
(week 36). Any deviations from this will be recorded on
a Protocol Deviations form. The longer term follow-up
is important to assess maintenance of any observed ef-
fect, and determine whether long-term engagement is
sustained once support from the treating physiotherapist
is withdrawn.
Measures have been selected on the basis of demon-
strated reliability and validity in assessing physical im-
pairments, clinical outcomes, quality of life, and
economic costs in people with MS.
Primary outcome measures
The primary clinical outcome is motor function,
assessed using the Amended Motor Club Assessment
(AMCA) [23]. This rates motor impairment of the lower
limb and trunk and key functional movements such as
sit-to-stand and standing balance. It was developed spe-
cifically for people with MS and has demonstrated valid-
ity, reliability and responsiveness [20, 23, 24]
The primary economic endpoint is the quality-adjusted
life year (QALY), assessed using the EuroQol five
dimensional descriptive system, the EQ-5D-5 L self re-
port measure [25].
Secondary outcome measures
A. Key clinical outcomes:
1. Bowel and bladder control using the self-report
Bladder and Bowel Control Scales [26]
2. Sitting balance using the single item Modified
Functional Reach in Sitting [27]
3. Falls frequency through a single yes/no question
“Did you fall today?”, recorded on the daily diary
4. Health-related quality-of-life (HRQoL), using the 29
item Multiple Sclerosis Impact Scale (MSIS-29
version 2.0) [28], a disease specific patient-reported
outcome measure with a preference-based tariff [29]
for use in sensitivity analyses for the Quality
Adjusted Life Year (QALY) outcome.
B. Explanatory physical impairments:
1. Knee extensor strength using a portable hand-held
dynamometer [30]
2. Length of hip flexors, hamstrings and ankle
plantarflexors using manual goniometry [16]
3. Spasm frequency using the Penn Spasm Frequency
Scale [31]
4. Respiratory capacity using a hand-held spirometer to
record forced expiratory volume at one second [32]
Measures of intervention adherence
A simple pre-formatted daily diary will be completed by
those allocated to the standing frame programme. Either
the participant or carer will record adherence with the
intervention (frequency, duration, reasons for not stand-
ing), and will also have the opportunity to comment on
why standing was continued or stopped. Adverse events
(including new symptoms and falls) will also be recorded
in the diary.
The usual care group will also be asked to complete a
daily diary to capture adverse events (including new
symptoms and falls).
Safety monitoring
Participants will be monitored for adverse events via
completion of their study daily diaries and during
follow-up assessments. The group receiving the inter-
vention will also be monitored during the scheduled
telephone calls with their treating physiotherapist. Phys-
iotherapists will be asked to report all adverse events to
the research team, whether or not they are thought to
be related to the intervention.
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Economic evaluation
The economic evaluation will estimate the cost effective-
ness of the standing frame programme plus usual care,
versus usual care alone. The primary perspective of the
analyses will be that of the NHS and Personal Social Ser-
vices (i.e. Third Party Payer), with a broader perspective
to be considered in sensitivity analyses. Cost effective-
ness analyses (CEA) will present an estimate of the in-
cremental cost per unit change in the primary outcome
measure (AMCA), but the primary economic analyses
will be the incremental cost per QALY gained (over
36 week follow-up). The EQ-5D-5 L will be the primary
economic endpoint used to estimate QALYs, applying a
UK tariff [33], at final follow-up, with the MSIS-8D [29]
used to estimate QALYS based on the MSIS-29, a condi-
tion specific measure. Economic analyses will estimate
the resource use (e.g. standing frames, physiotherapy
sessions, travel, telephone calls, social care assistance)
and related cost associated with delivery of the standing
frame programme, in addition to usual care, via data col-
lected within the trial.
Data will be collected, via a self-report Resource Use
Questionnaire, on participant use of health and social
care services (primary, secondary and social care), and
on broader aspects of participant and carer-related re-
source use.
Regression methods will be used to estimate incre-
mental costs and QALYs, adjusting for baseline (cost,
QALY) values, with covariates for baseline ACMA and
stratification variables (baseline EDSS, geographic re-
gions), and economic analyses will be consistent with
the primary statistical analysis plan. The CEA will syn-
thesise cost and outcome data, and explore uncertainty,
to present results of the economic evaluation in a policy
relevant way.
Qualitative assessment
A qualitative approach will be used to capture and ex-
plore the “real-life” experiences of people’s participation
in the standing frame programme. Purposive sampling
to achieve maximum variation will be used to request 10
participants and 10 carers to keep audio diaries of their
experiences of standing and using the frame. They will
be asked to use an audio recorder to record their reflec-
tions and experiences on how it feels to stand, changes
they are experiencing, plus any comments they wish to
make throughout the intervention period. To ensure
contemporaneous collection of data they will be asked
to record these reflections, if possible, during each stand
or as near to the completed standing period as possible.
Statistical analysis
A full statistical analysis plan will be developed and
approved by an independent statistician, prior to final
database-lock. The primary statistical analysis will utilise
analysis of covariance (ANCOVA), comparing AMCA
scores at week 36 between allocated groups, adjusting
for baseline AMCA score and the two stratification vari-
ables (baseline EDSS category and geographical region).
The primary comparative analyses of all outcome mea-
sures will be on the basis of intention-to-treat (adverse
events will be presented per protocol if different).
Between-group differences will be presented with 95 %
confidence intervals wherever possible, with the signifi-
cance level for hypothesis testing set at 5 %, unless
otherwise stated.
Secondary outcomes will be compared between groups
in a similar way to that for the primary outcome. Compar-
isons of interest will be presented with 95 % confidence
intervals for both unadjusted and adjusted between-group
comparisons.
Subgroup analyses
Exploratory analyses of the possible interaction between
baseline EDSS and allocated group will be undertaken,
to explore whether any difference between the allocated
groups is modified by baseline EDSS category (≤7.0
vs ≥7.5).
Qualitative analysis
Participants’ stories will be gathered, analysed and re-
ported using narrative methodology [34]. The texts from
audio recordings will be left whole, crafted into a story,
and not fractured into themes, as an attempt to capture
the immediate impact of standing, and to form a
chronological record of the person’s experience. This
promotes a contextual and holistic account; providing
stories that are intended to resonate with people with
MS, their families and professionals. By reading these
stories the aim is to encourage the reader to reflect on
their own situation gaining insight into their own experi-
ence as a person standing and living with MS, assisting a
person to stand or as a professional.
Data management, audit and monitoring
Data will be recorded on study specific data collection
forms by the research therapists. Completed forms will
be entered onto a password-protected customised data-
base, developed by the Peninsula CTU. All data will be
double entered and compared for discrepancies. Discrep-
ant data will be verified using the original paper data
sheets.
Participants’ anonymity will be maintained on all doc-
uments. Data will be collected and stored in accordance
with the Data Protection Act 1998, and will be accessible
for the purposes of monitoring, auditing, or at the re-
quest of the regulatory agency.
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Trial management committees
There are two trial management groups involved in the
set up and management of this trial: the Trial Manage-
ment Group (TMG) and the Trial Steering Committee
(TCS).
The TMG comprises 10 individuals involved in the
study design and protocol development. The group will
meet approximately monthly to oversee the general
management of the day to day running of the trial and
release the trial results and publications. Closely in-
volved with the sponsors, most members are co-
investigators on this study. In contrast the decisions
made by the TSC are independent of the sponsors and
investigators. The TSC, which meets annually, comprises
eight individuals, with majority independent representa-
tion (chair, external statistician, member of MS Society
and two independent lay members. In addition the chair
of the TSC will receive a quarterly update of the adverse
events, and a telephone conference / additional face-to-
face meeting will be instigated by the Chair or the Chief
Investigator should any issues need to be discussed.
The role of the TSC is to oversee the conduct of the
trial, including for instance monitoring adverse events,
recruitment and attrition rates, the project timeline and
finances.
Ethics
The trial will be conducted in accordance with the ethical
principles that have their origin in the Declaration of
Helsinki, 1996; the principles of Good Clinical Practice,
and the Department of Health Research Governance
Framework for Health and Social Care, 2005. The study
protocol, participant information and enrolment proce-
dures were assessed and approved through the National
Research Ethics Scheme (NRES Committee South West –
Frenchay, REC ref no. 15/SW/0088) and management
permissions gained from the Research and Development
Departments of the eight participating centres in
accordance with NHS research governance arrangements.
Any amendments to the protocol will be reported to, and
approved via NRES.
Dissemination plan
We will target users, clinicians, researchers, organisa-
tions developing clinical guidelines and NHS decision
makers. On completion of the trial, the full study report
will be accessible on the study web-site page, as will the
full protocol. This protocol (Version 3.0, dated 5.2.2015)
has been published in line with SPRIT Guidelines [35].
Similarly CONSORT (Consolidated Standards of Report-
ing Trials) [36] and The Template for Intervention
Description and Replication (TiDIER) Guidelines [37]
will be reviewed prior to submitting future publications
of the trial results to high quality journals. Authorship of
intended articles will be by the study team; professional
writers will not be used. Results will be presented at na-
tional and international conferences to ensure dissemin-
ation to academics and those responsible for service
delivery. In addition results will be disseminated through
the newsletters of MS organisations and via talks to their
local support groups. If proven effective, the training
materials (treatment manual, instructional video record-
ings, case scenarios) will be made freely available via the
study website, with the aim of optimising roll out. Ex-
tracts from the audio recordings will also be used as
educational and decision making tools for use by both
people with MS and therapists involved in their care. All
participants, who consent to receiving notifications, will
be notified in writing of trial outcomes.
Discussion
Preliminary evidence from two small-scale studies sug-
gests that the use of standing frames in the home may
improve physical and psychological well-being in people
with MS [16, 17]. This protocol describes the first large-
scale trial to evaluate the use of the standing frame in
this way. It is important to determine definitively whether
such a programme is clinically and cost effective so that
people affected by MS, clinicians, commissioners and pol-
icy makers can make informed evidence-based decisions
regarding the use of this intervention.
Some of the choices in the study design warrant dis-
cussion. First we discuss why our inclusion criteria were
confined to those individuals with progressive disease.
This is for two main reasons: the lack of disease-
modifying drugs for progressive MS which means that
management is aimed solely at minimising symptoms
and, if possible, improving function; and the paucity of
studies devoted to improving mobility in people with
progressive MS [38]. As a consequence there are few
proven interventions for these people. By testing the use
of standing frames in a multi-centre randomised con-
trolled trial, we may be able to identify a successful and
cost effective intervention. In doing so, the results have
the potential to change clinical practice and optimise
supported self-management within a population that re-
ceive little attention, yet are severely affected by their
condition.
The second relevant issue is the stratification by re-
gion and baseline disability level (as determined by the
EDSS ≤7.0 or ≥7.5). We stratified by region (South West
England versus East Anglia) because of possible differ-
ences in terms of usual care provided. Stratification by
disability level was included because of the potential dif-
ferences in ability of participants to adhere to the inter-
vention, and respond to it. We hypothesise that those
with higher levels of disability will have lower levels of
adherence and be at higher risk of drop out of the study.
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Furthermore, more severely impaired participants may
utilise greater levels of health and social service provision
which may bias the cost effectiveness and cost-utility
analyses.
Third, the dose (frequency and intensity) of the self-
management standing intervention and the time frame
over which this was increased was informed by a com-
bination of scientific and anecdotal evidence. The stand-
ing duration of 20 weeks factors in up to four weeks for
individuals to become gradually re-accustomed to an up-
right position and to steadily achieve the desired inten-
sity of standing (three times a week for 30 min per
session over 16 weeks) which was based on previous
studies [16, 17]. In doing so, we hope that it will minimise
fatigue, and allow for time when the participant is unable
to use the frame (illness, holidays, etc.), as highlighted by
our user discussion groups.
Fourth, a practical issue that we considered was which
of the various commercially available standing frames we
would utilise for this study. The Oswestry Standing
Frame was chosen because: (a) it is commonly used
within both the National Health Service, the charitable
sector (e.g. MS Centres), and within undergraduate
physiotherapy teaching, hence minimising the training
requirements for clinicians; (b) it is both durable and re-
cyclable, and hence can be recirculated for use within
the health service thereby enhancing sustainability; (c) it
is relatively lightweight (the frame can easily be pushed
across a floor by one person) which makes it easy to
move into a position for standing in the home and then
returned to a storage part of the room when not in use;
(d) it is used within current clinical practice in a range
of conditions (e.g. stroke, spinal cord injury, cerebral
palsy) and hence, should the results of this trial be nega-
tive, then it could continue to be recycled for use within
the health service; (e) it is one of the cheapest frames on
the market, and finally (e) it is wooden and hence per-
ceived by some patients as “more like a piece of furni-
ture”, which is an important consideration given that
these frames will be used within people’s homes.
Trial status
Recruitment started in September 2015 and is ongoing
(49 participants recruited as of 21st March 2016).
Ethics approval and consent to participate
The study protocol, participant information and enrol-
ment procedures were assessed and approved through
the National Research Ethics Scheme (NRES Commit-
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will be presented in the main paper or additional sup-
porting files.
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